Formulation and Biological Activity of Antineoplastic Proteoglycans Derived from Mycobacterium vaccae in Chitosan Nanoparticles
- 1 February 1999
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 51 (2), 151-157
- https://doi.org/10.1211/0022357991772268
Abstract
Although heat-killed suspensions of Mycobacterium vaccae have been tested clinically against tuberculosis and cancer, from a pharmaceutical perspective it would be advantageous to utilize isolated active components rather than the heat-degraded bacterial materials. In our laboratory we have isolated from M. vaccae a number of high-molecular-weight proteoglycans with considerable immunological and antineoplastic activity. The structure of one of these, PS4A, obtained by extraction with boiling water, seems to consist of a basic unit with a 20-kDa protein core to which are attached glucans and O-methylated 4-kDa polysaccharides. The molecular weight is (approx.) 50 kDa, but because of self-association, that of the recovered high-molecular-weight fraction is greater than 150 kDa. A similar, but even larger, molecule (PS4α, MW ∼20 MDa) is obtained by cold extraction with 8 M urea. Both are active in-vivo against an S-180 murine sarcoma model but have no activity in-vitro, suggesting an antitumour effect involving activated macrophages. For this reason gelatin nanoparticles are unsuitable as a vehicle but chitosan seemed to be a promising alternative. In this report we describe the production of stable 600–700-nm diameter nanoparticles of chitosan without organic solvents. Adsorption and release of bovine serum albumin seemed to be affected by the charge of the two reactants and at high doses not all adsorbate was released. PS4A, because of structural and compositional differences, had to be loaded on to the chitosan by freeze drying a suspension of the nanoparticles in a solution of the drug. After a rapid (burst) release phase, the rate of release into water was steady for the next 4h, but not all the drug was released. In-vivo it was evident that PS4A and PS4α were equally active in solution or when formulated in the chitosan nanoparticles. These results show that chitosan nanoparticles, readily prepared without the use of organic solvents, are a suitable vehicle for the delivery of these immunostimulants from M. vaccae; the formulations might find application as antitumour agents.Keywords
This publication has 21 references indexed in Scilit:
- Chitosan as a Nasal Delivery System: The Effect of Chitosan Solutions on in Vitro and in Vivo Mucociliary Transport Rates in Human Turbinates and VolunteersJournal of Pharmaceutical Sciences, 1997
- NASAL ADMINISTRATION OF MORPHINE-6-GLUCURONIDE IN SHEEP—A PHARMACOKINETIC STUDYBiopharmaceutics & Drug Disposition, 1996
- Preparation and characterization of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for anti-inflammatory drugsJournal of Controlled Release, 1996
- Chitosan/calcium alginate microcapsules for intestinal delivery of nitrofurantoinJournal of Microencapsulation, 1996
- 5-Fluorouracil-loaded chitosan microspheres: Preparation and release characteristicsJournal of Microencapsulation, 1996
- Controlled Release of Endothelial Cell Growth Factor from Chitosan-Albumin Microspheres for Localized Angiogenesis: In Vitro and in Vivo StudiesArtificial Cells, Blood Substitutes, and Immobilization Biotechnology, 1996
- Glutaraldehyde cross-linked chitosan microspheres as a long acting biodegradable drug delivery vehicle: studies on the in vitro release of mitoxantrone and in vivo degradation of microspheres in rat muscleBiomaterials, 1995
- In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymersInternational Journal of Pharmaceutics, 1992
- Optimized Formulation of Magnetic Chitosan Microspheres Containing the Anticancer Agent, OxantrazolePharmaceutical Research, 1992
- High-dose inhibition and low-dose enhancement of murine sarcoma growth exhibited by BCG vaccineCancer Letters, 1991